Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIA I DELGADO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1689672867
CMS profile
1123273
Location
HOMESTEAD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$80.00

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $80.00 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $56.63 3
Hologic Sales and Service, LLC $23.37 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIA I DELGADO

NPI 1689672867 · CMS profile ID 1123273

Allopathic & Osteopathic Physicians / Family Medicine

HOMESTEAD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689672867?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIA I DELGADO, NPI 1689672867, CMS profile ID 1123273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689672867?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARIA I DELGADO, NPI 1689672867, CMS profile ID 1123273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689672867?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARIA I DELGADO, NPI 1689672867, CMS profile ID 1123273, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1689672867?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $80.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $18.1611/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116404921 CMS
Hologic Sales and Service, LLC $23.3705/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084899650 CMS
GlaxoSmithKline, LLC. $14.6003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116266077 CMS
GlaxoSmithKline, LLC. $23.8701/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116252896 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $505.17 1
PY2023 $66.88 3
PY2024 $80.00 4
PY2025 $124.25 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $42,795.60 4
PY2024 Principal investigator $307,202.34 101
PY2023 Principal investigator $262,920.60 379
PY2022 Principal investigator $211,483.20 244
PY2021 Principal investigator $303,104.39 323
PY2020 Recipient $1,456.17 8
PY2020 Principal investigator $107,586.96 81
PY2019 Principal investigator $159,183.33 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

379 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $557.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767613
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $149.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767649
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767655
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $149.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767683
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $149.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767719
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767731
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $709.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767737
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767757
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $149.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767805
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $557.00 12/21/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767811
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,603.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766987
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766993
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039766999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/19/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039767333
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791059
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791409
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791418
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791429
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791441
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,603.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $929.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 11/27/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039778305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.00 11/02/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039777169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 11/02/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039777175
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039758587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039758593
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039758605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039758611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039758619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039801155
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039801161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039801177
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039801185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 09/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039801195
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757343
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757361
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757383
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757437
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757443
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757463
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757481
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $116.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757505
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757577
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757584
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757603
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757609
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757615
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757639
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $48.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757681
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757693
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799455
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799531
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799579
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799595
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799603
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799661
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799677
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799693
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $116.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799709
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799757
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799789
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799805
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $48.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799951
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799959
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $199.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $169.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $131.00 09/08/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039800009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757211
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757223
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757229
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757235
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757247
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757253
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757271
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,415.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039757313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799327
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799335
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799343
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799351
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799359
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799383
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799391
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,415.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799431
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 09/07/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039799447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764107
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764137
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764155
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039764161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039808967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039808981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809017
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809031
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809043
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809055
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809067
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 07/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039809081
Principal investigator 1 SANOFI PASTEUR INC. $1,790.00 07/10/2023 Non-covered Recipient Entity
Hmc Research,LLC
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 1035902097
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $490.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722633
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722639
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,341.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,341.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722681
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $490.00 06/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039722693
Principal investigator 1 SANOFI PASTEUR INC. $895.00 05/19/2023 Non-covered Recipient Entity
Hmc Research,LLC
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 1035902109
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $490.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715963
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $490.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039715995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716041
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $998.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 05/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039716073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/10/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039711533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/10/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039711555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/10/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039711565
Principal investigator 1 AstraZeneca UK Limited $34,313.40 04/26/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults with Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B) No dispute reported 06/30/2026 991131505
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 04/25/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039710877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728385
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,603.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728391
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,603.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $929.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $929.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 04/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039728433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039834913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039834933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039834953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039834973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835013
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835053
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $490.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835115
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835137
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 03/17/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039835157
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816751
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,372.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 02/16/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039816927
Principal investigator 1 SANOFI PASTEUR INC. $1,050.00 01/25/2023 Non-covered Recipient Entity
Hmc Research,LLC
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 1035902073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813431
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813463
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 01/18/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039813519
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $739.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853369
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853403
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853418
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $563.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,867.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853501
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853549
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $231.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853581
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853613
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,530.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,415.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,156.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $784.00 01/11/2023 Non-covered Recipient Entity
HMC RESEARCH LLC
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1039853677